CD22 is a transmembrane glycoprotein with a relative molecular mass of 135kDa. It has two types: α and β. The total length of human CD22 is 827 amino acids, including extracellular segment (668 amino acids), transmembrane region (19 amino acids) and intracellular Area (140 amino acids). CD22 is specifically expressed in B cells, and its expression is up-regulated in activated B cells. CD22 is a member of the B cell inhibitory receptor family and one of the co-receptors on the surface of B cells. CD22 forms a loose complex with the B cell receptor through the lectin-like domain in the extracellular zone. After cross-linking with BCR, it initiates an intracellular signal cascade, thereby modulating the BCR-mediated signal transduction pathway and the function of B cells. CAR-T targeting CD22 has been used in the treatment of B lymphocyte tumors. This product is the second generation of CAR lentiviral expression vector targeting CD22.

Product name: Lenti-EF1a-CD22-2nd-CAR-EGFRt

Promoter: EF1a[1]

Intracellular co-activation signal: 4-1BB/CD3Zata

Resistance gene: Amp

Label: EGFRt[2]



1. Compared with the CMV promoter, EF1a can be continuously expressed in immune cells, so it can significantly extend the expression of CAR in T cells.

2. EGFRt intercepts domain III and domain IV of wild-type EGFR. This truncated EGFRt has no intracellular signal and will not transmit other signals to T cells. At the same time, these two domains are cetuximab Recognizing the epitope and expressing the epitope on T cells can not only be used as CAR-T screening markers, but also add a safety switch for clinical research. Related flow cytometry antibodies can be inquired ( iCareAb, CAT# IAB006A )